Highlights Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
70.46 ^USD	-0.16%		+2.82%	-1.34%

Apr. 08	Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	CI
Apr. 03	Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	Apr. 08	CI
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics	Apr. 02	CI
Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance	Feb. 27	MT
Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024	Feb. 27	CI
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 Revenue $28.1M, vs. Street Est of $25.7M	Feb. 27	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 EPS $1.05, vs. Street Est of $0.66	Feb. 27	MT
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia...	Jan. 08
Ligand Pharmaceuticals Secures FDA Approval for Viral Skin Infection Medication; Shares Jump Premarket	Jan. 08	MT
Ligand Pharmaceuticals Gets FDA OK for Viral Skin Infection Treatment	Jan. 05	DJ
Ligand Pharma's at-home skin treatment gets FDA approval	Jan. 05	RE
Ligand Pharmaceuticals Secures FDA Approval for Viral Skin Infection Medication	Jan. 05	MT
Ligand Pharma's topical skin drug gets US FDA approval	Jan. 05	RE
U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum	Jan. 05	CI
Ligand Pharmaceuticals Sets 2024 Earnings, Revenue Guidance	Dec. 12	MT
Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024	Dec. 12	CI
Ligand Pharmaceuticals Expands Partnership With Palvella Therapeutics to Advance Qtorin	Dec. 01	MT
Tranche Update on Ligand Pharmaceuticals Incorporated's Equity Buyback Plan announced on August 8, 2023.	Nov. 09	CI
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q3 Revenue $32.9M, vs. Street Est of $27.2M	Nov. 08	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q3 EPS $1.02, vs. Street Est of $0.62	Nov. 08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Highlights

Filters